Table 3.
Antiproliferative activity of compounds 6, 10, 17, 18, 20 and 22 in gastric (EPG85-257), pancreatic (EPP85-181) and colon (HT-29) cancer cell models (Ramalhete et al. 2018)
| Compound | IC50 (μM) ± SD | IC50 (μM) ± SD | RR1 | IC50 (μM) ± SD | RR1 |
|---|---|---|---|---|---|
| EPG85-257P | EPG85-257RDB | EPG85-257RNOV | |||
| Balsaminol F (6) | 14.4 ± 3.8 | 6.2 ± 0.4 | 0.43 | 7.2 ± 0.7 | 0.50 |
| Balsaminoside A (10) | 9.5 ± 2.8 | > 100 | > 10.52 | 4.5 ± 2.5 | 0.47 |
| Karavilagenin C (17) | 7.9 ± 0.4 | 2.5 ± 0.4 | 0.32 | 6.6 ± 0.56 | 0.84 |
| HT-29P | HT-29RDB | HT-29RNOV | |||
|---|---|---|---|---|---|
| Karavilagenin C (17) | 13.8 ± 0.6 | 6.8 ± 1.4 | 0.49 | 6.7 ± 0.8 | 0.49 |
| Karavoate A (18) | 7.9 ± 3.1 | 3.1 ± 1.2 | 0.39 | 2.3 ± 0.0 | 0.29 |
| Karavoate C (20) | 13.8 ± 2.7 | 7.1 ± 0.0 | 0.51 | 4.9 ± 0.6 | 0.36 |
| Karavoate E (22) | 15.4 ± 0.5 | 6.9 ± 0.2 | 0.45 | 4.0 ± 1.1 | 0.26 |
| EPP85-181P | EPP85-181RDB | EPP85-181RNOV | |||
|---|---|---|---|---|---|
| Balsaminol F (6) | 15.4 ± 3.2 | 8.5 ± 0.9 | 0.55 | 11.7 ± 1.8 | 0.76 |
| Karavilagenin C (17) | 6.7 ± 0.2 | 6.8 ± 0.9 | 1.00 | 6.7 ± 2.3 | 1.00 |
1RR (relative resistance ratio) = IC50(resistant)/IC50(parental)). RR < 1: MDR-selective antiproliferative effect; RR ≤ 0.5: collateral sensitivity effect.